Functional analysis of germline ETV6 variants associated with familial thrombocytopenia and acute lymphoblastic leukemia

Rebekah Baskin,Rina Nishii,Javad Nadaf,Katherine Verbist,Paige Tedrick,Keito Hoshitsuki,Maoxiang Qian,Takaya Moriyama,Chunliang Li,Lewis B. Silverman,Melissa Burns,Ching-Hon Pui,Charles G. Mullighan,Kim E. Nichols,Jun Yang

DOI: https://doi.org/10.1016/j.exphem.2017.06.320

IF: 3.249

2017-01-01

Experimental Hematology

Abstract:Acute lymphoblastic leukemia (ALL) is the most common childhood cancer and a leading cause of pediatric morbidity and mortality despite high cure rates. Common and rare germline genetic variants can influence the risk of developing childhood ALL. Recently, we and others identified heterozygous germline ETV6 mutations associated with hereditary thrombocytopenia and increased risk for hematologic malignancies, particularly ALL (also known as Thrombocytopenia 5). Sequencing of 4,405 childhood ALL cases identified 30 potentially damaging germline ETV6 variants in 35 patients. We conducted a systematic in vitro evaluation of these variants by examining transcriptional repressor activity, DNA binding, nuclear localization and homo-dimerization. We found that of the 30 variants, 18 including 13 of the 14 variants in the ETS/DNA binding domain impaired transcriptional repression activity via a putative dominant-negative mechanism. These 18 variants also showed impaired nuclear localization and DNA binding capacity yet maintained the ability to dimerize with wild-type ETV6. By whole genome sequencing, we identified several recurrent somatic variants, including activating KRAS or NRAS mutations in 3 of 6 leukemia samples from patients harboring damaging germline ETV6 variants. To further understand the biological role of ETV6 mutations in the development of thrombocytopenia and ALL, we used a CRISPR-Cas9 mediated homology directed repair (HDR) strategy to create a genetically modified mouse model expressing the murine equivalent of the damaging variant R359X, which introduces a stop codon within the ETS domain of ETV6. We found that heterozygous mice harboring this truncating mutation displayed thrombocytopenia consistent with patients carrying the deleterious ETV6 variants. In summary, we have systematically characterized 30 germline ETV6 variants associated with ALL risk, identified potential cooperating somatic events in ALL with germline ETV6 variants, and established a mouse model of ETV6-associated thrombocytopenia. This mouse model is a critical tool to further assess the relationship between germline ETV6 mutations and development of thrombocytopenia and/or ALL.